SION-676

SION-676 is a small molecule drug in preclinical development for the treatment of cystic fibrosis. It is being developed by Sionna Therapeutics. The compound acts as a modulator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, specifically targeting the transmembrane domain 1 (TMD1) of CFTR. This mechanism is designed to correct defects caused by mutations such as ΔF508, which lead to improper folding and malfunction of CFTR and are responsible for most cases of cystic fibrosis. By targeting TMD1, SION-676 aims to restore normal function to mutant CFTR proteins and improve clinical outcomes for patients with cystic fibrosis[1][2][5][9].